San Diego-based NovaCardia, a company developing pharaceuticals for the treatment of cardiovascular disease based on small molecule drugs, said this morning it has raised $48M in a Series B funding. The funding was led by Skyline Ventures, and also included new investor InterWest Partners. Prior investors Domain Associates, Forward Ventures, Montreux Equity Partners, and Versant Ventures also participated in the round. More information »